The global nasal corticosteroids market is booming, projected to reach US$ 11.4 billion by 2034, fueled by increasing prevalence of chronic respiratory diseases like allergic and non-allergic rhinitis, and advancements in drug delivery. Key players like Sanofi, GSK, and AstraZeneca are driving innovation and expanding market access.